Replies to post #39311 on Biotech Values

[DewDiligence]

> GENR – After the demise of the AMD program, do you see any value in GENR's early stage programs like the Medimmune IL-9 antibody.<

If any of their early-stage programs has value, it would be the IL-9 program that is in MEDI’s hands. But I would not count on a lot of value even there—it took 5.5 years from the start of the collaboration in 2001 just to get through phase-1. Really good drugs generally move through development faster than that.

What else does GENR have? The aminosterol drug for obesity has been in preclinical development for a decade and has virtually zero chance to go anywhere, IMO. It’s a smokescreen to defect attention from the failings in AMD. Regards, Dew

p.s. I’m still contemplating your post about investing in biopharmaceuticals in the third world. You asked some good questions.